Robert Paul Biography and Net Worth

Insider of Alector

Robert has served as our Chief Medical Officer since October 2016. Robert joined Alector from Genentech, Inc., where he held various roles of increasing responsibility between 2009 and 2016, including as Assistant Group Medical Director and TA Head Neuroscience Early Clinical Development in gRED from October 2015 to October 2016, as Senior Medical Director from October 2013 to September 2015, as Medical Director from September 2011 to October 2013, and as Associate Medical Director from January 2009 to September 2011. From May 2002 to December 2008, Robert served as a Neurologist at the University of Munich. Robert is a board certified neurologist in Germany. He holds an M.D. and a Ph.D. from Ludwig-Maximilians Universität München.

What is Robert Paul's net worth?: The estimated net worth of Robert Paul is at least $481,060.58 as of July 6th, 2021. Dr. Paul owns 264,319 shares of Alector stock worth more than $481,061 as of December 26th. This net worth evaluation does not reflect any other investments that Dr. Paul may own. Learn More about Robert Paul's net worth.
How do I contact Robert Paul?: The corporate mailing address for Dr. Paul and other Alector executives is 131 OYSTER POINT BLVD. SUITE 600, SOUTH SAN FRANCISCO CA, 94080. Alector can also be reached via phone at (415) 231-5660 and via email at [email protected]. Learn More on Robert Paul's contact information.
Has Robert Paul been buying or selling shares of Alector?: Robert Paul has not been actively trading shares of Alector during the last quarter. Most recently, Robert Paul sold 22,950 shares of the business's stock in a transaction on Monday, August 9th. The shares were sold at an average price of $27.18, for a transaction totalling $623,781.00. Learn More on Robert Paul's trading history.
Who are Alector's active insiders?: Alector's insider roster includes Robert King (Insider), Robert Paul (Insider), Arnon Rosenthal (CEO), Richard Scheller (Director), Shehnaaz Suliman (COO), and Calvin Yu (VP). Learn More on Alector's active insiders.
Are insiders buying or selling shares of Alector?: During the last year, insiders at the sold shares 13 times. They sold a total of 224,032 shares worth more than $929,708.76. The most recent insider tranaction occured on December, 2nd when CFO Marc Grasso sold 16,489 shares worth more than $41,552.28. Insiders at Alector own 9.1% of the company. Learn More about insider trades at Alector.
Information on this page was last updated on 12/2/2024.

Robert Paul Insider Trading History at Alector

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/9/2021	Sell	22,950	$27.18	$623,781.00
7/6/2021	Sell	30,000	$37.31	$1,119,300.00	264,319
7/2/2021	Sell	30,000	$31.14	$934,200.00
6/15/2021	Sell	30,000	$22.07	$662,100.00	290,819
6/8/2021	Sell	19,175	$19.18	$367,776.50	281,011
5/21/2021	Sell	14,975	$18.14	$271,646.50	287,910
5/18/2021	Sell	4,200	$18.04	$75,768.00	276,619
4/7/2021	Sell	22,300	$19.20	$428,160.00	230,811
3/23/2021	Sell	13,800	$22.21	$306,498.00	243,719
3/9/2021	Sell	19,175	$18.12	$347,451.00	230,811
2/9/2021	Sell	19,175	$20.81	$399,031.75	230,810
1/26/2021	Sell	27,308	$18.00	$491,544.00	241,635
1/19/2021	Sell	30,000	$18.12	$543,600.00	241,636
7/15/2020	Sell	10,000	$22.96	$229,600.00	214,097
6/15/2020	Sell	10,000	$29.61	$296,100.00	227,628
4/15/2020	Sell	10,000	$22.27	$222,700.00	243,719
3/13/2020	Sell	10,000	$22.93	$229,300.00	262,238
1/30/2020	Sell	8,000	$28.00	$224,000.00	281,719
1/15/2020	Sell	10,000	$18.67	$186,700.00	273,719
10/15/2019	Sell	10,000	$15.01	$150,100.00
9/20/2019	Sell	4,000	$20.00	$80,000.00
9/16/2019	Sell	10,000	$19.08	$190,800.00
8/20/2019	Sell	2,000	$16.00	$32,000.00
8/15/2019	Sell	10,000	$14.19	$141,900.00	323,719

Robert Paul Buying and Selling Activity at Alector

Alector Company Overview

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

Today's Range

Now: $1.82

$1.78

$1.92

50 Day Range

MA: $3.63

$1.78

$6.06

2 Week Range

Now: $1.82

$1.73

$8.90

Volume

1,442,497 shs

Average Volume

769,126 shs

Market Capitalization

$178.24 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.51

Why Buffett, Griffin and 100 members of Congress are Piling into this One Investment

From Behind the Markets | Ad

This isn't just another investment. It might be the last retirement stock you'll ever need. But this window of opportunity is closing fast.

Click here for the ticker >>>